Chugai Pharmaceutical (OTCMKTS:CHGCY) Lowered to “Hold” Rating by UBS Group

Chugai Pharmaceutical (OTCMKTS:CHGCY) was downgraded by UBS Group from a “strong-buy” rating to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

Several other research analysts also recently commented on the company. The Goldman Sachs Group upgraded Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Performance

Shares of OTCMKTS:CHGCY opened at $21.66 on Thursday. Chugai Pharmaceutical has a 52-week low of $20.00 and a 52-week high of $34.84. The company has a market capitalization of $71.29 billion, a P/E ratio of 23.54 and a beta of 0.60. The company has a 50-day simple moving average of $22.70 and a 200 day simple moving average of $26.02.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. The firm had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.71% and a net margin of 35.09%. As a group, equities analysts forecast that Chugai Pharmaceutical will post 0.96 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.